mRNA-1010, an mRNA-Based Influenza Vaccine, is Safe and Efficacious in Adults Aged ≥50 Years, Including Individuals at High Risk for Severe Disease

A real-life study revealed the presence of more than 10% nirsevimab escape mutants in RSV-B breakthrough infections.

Prior immunity with seasonal influenza A(H3N2) virus confers varying levels of protection against clade 2.3.4.4b A(H5N1), A(H7N9), or A(H9N2) virus challenge in a ferret model

Adjuvanted inactivated zoonotic influenza A(H5N8) vaccination induces antibody and T-cell responses to emerging HPAI clade 2.3.4.4b A(H5N1) viruses in healthcare workers

Translational efficacy of CD388, a novel Drug Fc-Conjugate (DFC), in mouse influenza infection models: application to prevention efficacy in the recently completed Ph2b NAVIGATE clinical study

Effectiveness of HD-IIV against laboratory-confirmed influenza infection and patient-centered outcomes in the community: a DANFLU-2 sub-study

Induction of strong innate immune response in human alveolar epithelium is correlated with pathogenicity of avian influenza viruses